Nonin vasi ve assessment of treatment of cardiac allograft rejection with indium-111-labeled lymphocytes

Michael Rosenbloom, Howard Eisen, John Laschinger, Jeffrey E. Saffitz, Burton E. Sobel, Steven R. Bergmann, R. Morton Bolman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We have shown previously that cardiac allograft rejection can be detected noninvasively with gamma scin-tigraphy after administration of indium-111 (111In)-la beled lymphocytes. To determine whether this technique could be used to monitor salvage immunosuppressive therapy in reversing rejection, 5 dogs were studied after thoracic heterotopic cardiac transplantation. Initial postoperative immunosuppression was maintained with cyclosporine (10—20 mg/kg/day) and prednisone (1 mg/ kg/day) for 7 days after transplantation and then dis-continued. Scintigraphy after administration of labeled lymphocytes was performed during initial immuno-suppression and every 3 days after its termination. Endomyocardial biopsies were obtained on each day scin-tigraphy was performed. Once scintigraphic criteria for rejection were met (111In-lymphocyte uptake > mean ± 2SD of normal myocardium), animals were treated with high dose methylprednisolone and cyclosporine. Myocardial 111In-lymphocyte activity compared with that in blood was 0.7±0.8 during initial immunosuppression, increased to 5.7±3.5 after termination of therapy (P<0.01), and diminished with salvage immunosuppressive therapy to 0.5±0.8 (P=NS compared with native hearts or allografts during initial immunosuppression). Scintigraphy accurately predicted all but one episode of biopsy-documented rejection and accurately detected reversal of rejection during salvage. Thus, scintigraphy with 111In-labeled lymphocytes should facilitate noninvasive monitoring of antirejection therapy in patients.

Original languageEnglish (US)
Pages (from-to)341-346
Number of pages6
JournalTransplantation
Volume46
Issue number3
StatePublished - Jan 1 1988

Fingerprint

Indium
Allografts
Immunosuppression
Lymphocytes
Radionuclide Imaging
Salvage Therapy
Immunosuppressive Agents
Cyclosporine
Heterotopic Transplantation
Biopsy
Therapeutics
Methylprednisolone
Heart Transplantation
Prednisone
Myocardium
Thorax
Transplantation
Dogs

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Rosenbloom, M., Eisen, H., Laschinger, J., Saffitz, J. E., Sobel, B. E., Bergmann, S. R., & Bolman, R. M. (1988). Nonin vasi ve assessment of treatment of cardiac allograft rejection with indium-111-labeled lymphocytes. Transplantation, 46(3), 341-346.
Rosenbloom, Michael ; Eisen, Howard ; Laschinger, John ; Saffitz, Jeffrey E. ; Sobel, Burton E. ; Bergmann, Steven R. ; Bolman, R. Morton. / Nonin vasi ve assessment of treatment of cardiac allograft rejection with indium-111-labeled lymphocytes. In: Transplantation. 1988 ; Vol. 46, No. 3. pp. 341-346.
@article{dee485b13bcf4218aaceb6fcc72b2f63,
title = "Nonin vasi ve assessment of treatment of cardiac allograft rejection with indium-111-labeled lymphocytes",
abstract = "We have shown previously that cardiac allograft rejection can be detected noninvasively with gamma scin-tigraphy after administration of indium-111 (111In)-la beled lymphocytes. To determine whether this technique could be used to monitor salvage immunosuppressive therapy in reversing rejection, 5 dogs were studied after thoracic heterotopic cardiac transplantation. Initial postoperative immunosuppression was maintained with cyclosporine (10—20 mg/kg/day) and prednisone (1 mg/ kg/day) for 7 days after transplantation and then dis-continued. Scintigraphy after administration of labeled lymphocytes was performed during initial immuno-suppression and every 3 days after its termination. Endomyocardial biopsies were obtained on each day scin-tigraphy was performed. Once scintigraphic criteria for rejection were met (111In-lymphocyte uptake > mean ± 2SD of normal myocardium), animals were treated with high dose methylprednisolone and cyclosporine. Myocardial 111In-lymphocyte activity compared with that in blood was 0.7±0.8 during initial immunosuppression, increased to 5.7±3.5 after termination of therapy (P<0.01), and diminished with salvage immunosuppressive therapy to 0.5±0.8 (P=NS compared with native hearts or allografts during initial immunosuppression). Scintigraphy accurately predicted all but one episode of biopsy-documented rejection and accurately detected reversal of rejection during salvage. Thus, scintigraphy with 111In-labeled lymphocytes should facilitate noninvasive monitoring of antirejection therapy in patients.",
author = "Michael Rosenbloom and Howard Eisen and John Laschinger and Saffitz, {Jeffrey E.} and Sobel, {Burton E.} and Bergmann, {Steven R.} and Bolman, {R. Morton}",
year = "1988",
month = "1",
day = "1",
language = "English (US)",
volume = "46",
pages = "341--346",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Rosenbloom, M, Eisen, H, Laschinger, J, Saffitz, JE, Sobel, BE, Bergmann, SR & Bolman, RM 1988, 'Nonin vasi ve assessment of treatment of cardiac allograft rejection with indium-111-labeled lymphocytes', Transplantation, vol. 46, no. 3, pp. 341-346.

Nonin vasi ve assessment of treatment of cardiac allograft rejection with indium-111-labeled lymphocytes. / Rosenbloom, Michael; Eisen, Howard; Laschinger, John; Saffitz, Jeffrey E.; Sobel, Burton E.; Bergmann, Steven R.; Bolman, R. Morton.

In: Transplantation, Vol. 46, No. 3, 01.01.1988, p. 341-346.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nonin vasi ve assessment of treatment of cardiac allograft rejection with indium-111-labeled lymphocytes

AU - Rosenbloom, Michael

AU - Eisen, Howard

AU - Laschinger, John

AU - Saffitz, Jeffrey E.

AU - Sobel, Burton E.

AU - Bergmann, Steven R.

AU - Bolman, R. Morton

PY - 1988/1/1

Y1 - 1988/1/1

N2 - We have shown previously that cardiac allograft rejection can be detected noninvasively with gamma scin-tigraphy after administration of indium-111 (111In)-la beled lymphocytes. To determine whether this technique could be used to monitor salvage immunosuppressive therapy in reversing rejection, 5 dogs were studied after thoracic heterotopic cardiac transplantation. Initial postoperative immunosuppression was maintained with cyclosporine (10—20 mg/kg/day) and prednisone (1 mg/ kg/day) for 7 days after transplantation and then dis-continued. Scintigraphy after administration of labeled lymphocytes was performed during initial immuno-suppression and every 3 days after its termination. Endomyocardial biopsies were obtained on each day scin-tigraphy was performed. Once scintigraphic criteria for rejection were met (111In-lymphocyte uptake > mean ± 2SD of normal myocardium), animals were treated with high dose methylprednisolone and cyclosporine. Myocardial 111In-lymphocyte activity compared with that in blood was 0.7±0.8 during initial immunosuppression, increased to 5.7±3.5 after termination of therapy (P<0.01), and diminished with salvage immunosuppressive therapy to 0.5±0.8 (P=NS compared with native hearts or allografts during initial immunosuppression). Scintigraphy accurately predicted all but one episode of biopsy-documented rejection and accurately detected reversal of rejection during salvage. Thus, scintigraphy with 111In-labeled lymphocytes should facilitate noninvasive monitoring of antirejection therapy in patients.

AB - We have shown previously that cardiac allograft rejection can be detected noninvasively with gamma scin-tigraphy after administration of indium-111 (111In)-la beled lymphocytes. To determine whether this technique could be used to monitor salvage immunosuppressive therapy in reversing rejection, 5 dogs were studied after thoracic heterotopic cardiac transplantation. Initial postoperative immunosuppression was maintained with cyclosporine (10—20 mg/kg/day) and prednisone (1 mg/ kg/day) for 7 days after transplantation and then dis-continued. Scintigraphy after administration of labeled lymphocytes was performed during initial immuno-suppression and every 3 days after its termination. Endomyocardial biopsies were obtained on each day scin-tigraphy was performed. Once scintigraphic criteria for rejection were met (111In-lymphocyte uptake > mean ± 2SD of normal myocardium), animals were treated with high dose methylprednisolone and cyclosporine. Myocardial 111In-lymphocyte activity compared with that in blood was 0.7±0.8 during initial immunosuppression, increased to 5.7±3.5 after termination of therapy (P<0.01), and diminished with salvage immunosuppressive therapy to 0.5±0.8 (P=NS compared with native hearts or allografts during initial immunosuppression). Scintigraphy accurately predicted all but one episode of biopsy-documented rejection and accurately detected reversal of rejection during salvage. Thus, scintigraphy with 111In-labeled lymphocytes should facilitate noninvasive monitoring of antirejection therapy in patients.

UR - http://www.scopus.com/inward/record.url?scp=0023736754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023736754&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 341

EP - 346

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 3

ER -

Rosenbloom M, Eisen H, Laschinger J, Saffitz JE, Sobel BE, Bergmann SR et al. Nonin vasi ve assessment of treatment of cardiac allograft rejection with indium-111-labeled lymphocytes. Transplantation. 1988 Jan 1;46(3):341-346.